Qiagen (QGEN) Projected to Post Quarterly Earnings on Tuesday

Qiagen (NYSE:QGEN) is projected to issue its Q3 2025 results after the market closes on Tuesday, November 4th. Analysts expect the company to announce earnings of $0.59 per share and revenue of $525.6760 million for the quarter. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS.Interested persons may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, November 5, 2025 at 9:30 AM ET.

Qiagen (NYSE:QGEN) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 EPS for the quarter, meeting the consensus estimate of $0.60. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The business had revenue of $533.54 million during the quarter, compared to analyst estimates of $523.97 million. During the same quarter last year, the firm posted $0.55 earnings per share. The business’s revenue for the quarter was up 7.7% compared to the same quarter last year. On average, analysts expect Qiagen to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Qiagen Price Performance

Shares of QGEN opened at $46.86 on Monday. The company has a market cap of $10.42 billion, a P/E ratio of 27.68, a PEG ratio of 2.48 and a beta of 0.66. Qiagen has a fifty-two week low of $37.63 and a fifty-two week high of $51.88. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25. The firm’s 50 day moving average price is $46.82 and its 200 day moving average price is $46.42.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in QGEN. Osaic Holdings Inc. raised its position in shares of Qiagen by 101.4% during the 2nd quarter. Osaic Holdings Inc. now owns 3,875 shares of the company’s stock worth $185,000 after acquiring an additional 1,951 shares in the last quarter. Pitcairn Co. purchased a new position in Qiagen in the second quarter valued at approximately $208,000. Evergreen Capital Management LLC purchased a new position in Qiagen in the second quarter valued at approximately $246,000. Captrust Financial Advisors acquired a new stake in Qiagen during the second quarter worth approximately $221,000. Finally, Orion Porfolio Solutions LLC lifted its position in shares of Qiagen by 120.6% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 29,361 shares of the company’s stock worth $1,411,000 after buying an additional 16,054 shares during the last quarter. 70.00% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

QGEN has been the topic of a number of recent research reports. Wall Street Zen raised Qiagen from a “hold” rating to a “buy” rating in a research report on Saturday. Cowen reissued a “hold” rating on shares of Qiagen in a research note on Thursday, August 7th. Barclays set a $53.00 price target on Qiagen and gave the stock an “overweight” rating in a report on Thursday, October 2nd. UBS Group lifted their price objective on Qiagen from $48.00 to $50.00 and gave the company a “neutral” rating in a research note on Thursday, August 7th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Qiagen in a research note on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Qiagen currently has an average rating of “Hold” and a consensus price target of $49.69.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.